Moderna Trading Guide: How to Trade Moderna (MRNA)
On 19 August 2026, Moderna closed at $174.38. The session before, it had closed at $62.96. One trading day added 177% to the share price and lifted the company's market value from about $25 billion to roughly $69 billion. The next session, the stock gave back nearly a quarter of that.
Those two days tell you most of what you need to know about trading MRNA right now. The moves are huge, they run in both directions, and they arrive on headlines rather than on a schedule.
This guide shows you how to trade Moderna's swings, not how to buy Moderna and hold it for a decade. It covers what triggered the rally, where the stock stands today, what drives its price movements, when it trades, and how to start trading Moderna share CFDs on MetaTrader 4 and 5, with the risk controls a stock this volatile demands.
What Is Moderna?
Moderna Inc. is a biotechnology company based in Cambridge, Massachusetts, built around messenger ribonucleic acid, better known as messenger RNA or mRNA. Instead of manufacturing a protein drug in a factory, it delivers genetic instructions that tell the body's own cells to make the protein. Its stated aim is a new class of transformative medicines based on mRNA. Turning that promise into approved new drugs, let alone life-changing medicines, has been slower outside COVID-19.
Historically, Moderna was founded in 2010 as Moderna Therapeutics by the venture firm Flagship Pioneering, and Stéphane Bancel has been chief executive officer since 2011. Its research is organized into modalities that include prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
The pipeline covers infectious diseases, rare diseases, and autoimmune diseases, with vaccine work spanning respiratory viruses, latent viruses such as Epstein-Barr virus, and public health vaccines for outbreak threats. Early backers and partners included Merck, AstraZeneca, Vertex Pharmaceuticals Incorporated (on a cystic fibrosis therapy), and the Bill & Melinda Gates Foundation.
Moderna went public on Nasdaq in December 2018, pricing shares at $23 in an IPO widely reported at $621 million, the largest biotech listing on record at the time. Before the pandemic, the stock mostly traded in the $20s or lower while investors waited for its first approved product.
Then came the COVID-19 vaccine. With development funding from the US Biomedical Advanced Research and Development Authority (BARDA), the Moderna vaccine was among the first authorized in the US, and investor confidence in COVID-19 vaccines sent the shares soaring. Moderna's stock price rose 858.52% from February 2020 to February 2021, and in August 2021 the stock peaked at around $485. It stayed elevated for a while, with an average stock price of around $150 in 2022. Then pandemic revenue faded, net income turned negative, and the shares slid to a 52-week low of $22.28 in 2025. That's until the recent news in 2026, which, once again, pushed the stock price higher.
Moderna Stock Performance
On 19 August 2026, Moderna announced, together with Merck, that the Phase 3 INTerpath-001 trial had met its primary endpoint. The study tested intismeran autogene, a personalized mRNA cancer therapy, alongside Merck's immunotherapy Keytruda in patients whose high-risk melanoma had been surgically removed. The combination improved recurrence-free survival compared with Keytruda alone.
It was the first positive Phase 3 result for any mRNA-based cancer therapy. Each dose is built from the patient's own tumor sample, so the market read the result as proof that the platform works in immuno-oncology, not just as a win for one product.
Moderna's latest quarterly filing lists nine Phase 2 and Phase 3 trials for intismeran across melanoma, lung, bladder, and kidney cancer. Success in one raised the odds the market priced into the rest. That's why investors are closely watching Moderna's programs beyond COVID-19: for biotech companies, positive trial results can reset the stock price overnight.
As a result, over the past year, Moderna's stock price has fluctuated between $22.28 and $199.82. Following the spike, it has chopped to trade between roughly $130 and $160, with daily ranges of $10 or more. On a $150 stock, that's a 6% to 7% swing in a single session, which many large-cap shares take a month to cover. But in mid to late September, the stock price, once again, spiked to trade around $200. This rally has been driven largely by strong Phase 3 results for its personalized mRNA cancer vaccine, alongside renewed investor confidence in its broader pipeline and recent regulatory developments.
Generally, biotech stocks have experienced high volatility lately because of regulatory approvals and shifts in market sentiment, and MRNA sits at the far end of that spectrum. A stop that works on a quiet blue chip gets hit by routine noise here. Knowing what drives the stock helps you decide when to be in it and when to step aside.
What Moves Moderna's Share Price
MRNA rarely drifts. It jumps, and almost every jump traces back to one of four catalysts: trial and regulatory news, earnings, analyst calls, or the price levels traders are watching on the chart. Here's how each one moves the stock:
Clinical and Regulatory News
Trading biotech stocks means trading clinical trial results, and nothing moves MRNA like trial data. The melanoma result still has to be presented in full at a medical meeting and filed with regulators, and every step is a potential headline. Readouts from the lung, bladder, and kidney trials carry the same binary risk: good data can add billions to the market value, and a miss can take it away just as fast.
Moderna also expects pivotal rare disease data this year, including for its propionic acidemia therapy, and potential approvals of flu and flu/COVID combination vaccines.
Market sentiment can shift on any of these vaccine developments or pipeline updates, and on news from rivals too: results from other mRNA or cancer vaccine developers, such as BioNTech, or a safety signal in any trial can move the whole group.
Earnings and Cash Burn
Moderna reports earnings quarterly. Revenue for 2025 came in around $1.9 billion, and management has guided to up to 10% revenue growth in 2026. Because the company still posts losses rather than profit, traders focus on cash, costs, and pipeline timelines.
Moderna doesn't pay dividends, so its dividend yield is zero and returns come only from price moves. The next big scheduled event is Moderna's Analyst Day on 12 November.
Technical levels
Because Moderna is a volatility-driven momentum stock, major highs and lows can quickly become significant technical levels. Before the recent spike, the $176.66 high from announcement day was the key resistance point. With MRNA now pushing higher, the $200 level has emerged as a major psychological and technical level to watch.
On the downside, buyers have repeatedly stepped in around $128–$135 since August, making this a notable support zone. A clean break above $200 could attract further momentum buying, while a rejection at the level could lead to a pullback toward lower support areas.
For technical analysis, many MRNA traders combine these key price levels with indicators such as moving averages, the Relative Strength Index (RSI), and the Average True Range (ATR) to assess momentum and help determine stop-loss distances.
When Can You Trade Moderna?
Moderna shares are traded on Nasdaq under the ticker MRNA, from 9:30 am to 4:00 pm Eastern Time. That makes Moderna stock trading hours Monday to Friday, 2:30 pm to 9:00 pm UK time, except for a few weeks in spring and autumn when US and UK clocks change on different dates. Liquidity is deepest, and spreads are tightest during this window, especially in the first and last hour.
Pre-market trading starts as early as 4:00 am ET and after-hours runs to 8:00 pm ET, but volume is thin and spreads widen. Moderna often releases trial results and earnings outside regular hours, which is why the stock so often gaps at the open. Share CFD prices follow the underlying cash session, so an order you place overnight fills when the market opens, at whatever price it opens at.
Ways to Trade Moderna: Shares, CFDs, and Options
There are three common ways to trade MRNA. They differ in cost, leverage, and how easily you can bet on a fall.
Buying physical shares
Buying physical shares is the most conventional way to invest in Moderna. You can buy MRNA through your bank, a traditional brokerage firm, or an online investment platform and hold the shares in your account.
The main advantages are no expiry date and no overnight financing charges. However, you need the full position value in capital, while profiting from a falling share price generally requires short selling, which can involve borrowing costs, margin requirements, and additional risk.
Trading Moderna CFDs
Moderna shares can be traded via derivatives like CFDs. A contract for difference (CFD) tracks the share price without transferring ownership, and MRNA CFDs are priced in US dollars, just like the stock. One CFD equals one share, so your exposure is easy to follow. You can buy if you expect the price to rise, and short-selling lets you profit from falling Moderna share prices, which matters on a stock trading this far above consensus. If you're new to the product, our beginner's guide to trading CFDs walks through how the mechanics work.
Trading CFDs on Moderna also allows for leveraged positions, so you post only a fraction of the position's value as margin. Switch Markets offers commission-free share CFDs with leverage of up to 1:10, depending on your account and jurisdiction. Say you open 20 MRNA CFDs at $154. That's $3,080 of exposure for about $308 in margin. A $15 move, which MRNA has made in a single day many times since August, changes the position's value by $300, close to the entire margin. Positions held past the daily cut-off also incur overnight financing (swap) charges.
Using options
Options provide another way to trade MRNA without buying the shares directly. Call options can be used when expecting the stock to rise, while put options can provide exposure to a potential decline. The maximum loss for an option buyer is generally limited to the premium paid.
However, options have an expiry date and their value is affected by factors such as time decay and implied volatility. Premiums can also become significantly more expensive ahead of major events such as clinical results or earnings, meaning traders may pay a high price for the move they are anticipating.
How to Trade MRNA CFDs on MT5 With Switch Markets
Here's the sequence from zero to a first MRNA trade.
- Open an account. Start with a free demo account, which never expires, so you can practice on real market prices first. When you're ready, verify your identity and deposit funds to open a live account from $50. Share CFDs sit alongside forex, indices, and other assets in the same account.
- Install MetaTrader 5. Download MT5 for Windows, iOS, Android, or the web. Mac users can follow our guide to installing MetaTrader on a Mac.
- Find the symbol. Open the Market Watch window, right-click, and choose Symbols. Search for Moderna or MRNA, which you'll usually find in the US shares group, and add it to your watchlist.
- Read the chart. Use the M15 and H1 timeframes for intraday trades, H4 and daily for swings. Mark key levels to watch, and add ATR to gauge how far price typically travels in a session under current market conditions.
- Size the trade before you place it. Decide where your stop loss goes, then work out the position size that keeps the loss within your limit. The free Risk Manager EA does the maths inside MetaTrader. On a stock this fast, pending orders at planned levels usually beat chasing with market orders.
- Manage the position. Attach your stop loss and take profit to the order, set price alerts at key levels, and use a trailing stop if a breakout runs in your favor.
Risk Management for Trading a High-Volatility Stock
Pharmaceutical companies must manage risk because so much depends on clinical trial outcomes. When you trade their shares, you inherit that dependency. On MRNA, your entry matters less than how much you risk and what happens when the price jumps past your stop. These three rules do most of the work, and remember that 1:10 leverage is a ceiling, not a target.
Size from the stop, not from conviction
Many traders cap risk at 1% to 2% of the account per trade, a rule we explain in five risk management techniques for day traders. On a $10,000 account, 2% is $200. If your stop sits $8 below entry, the maximum position is 25 CFDs ($200 ÷ $8). At $154, that's $3,850 of exposure, or about $385 in margin at 1:10. If you'd rather not do the arithmetic by hand, see how to use a position size calculator.
Use hard stops, and know their limits
Every MRNA trade needs a stop loss. But a stop is an instruction to close at the next available price, not a guarantee. When Redburn's downgrade hit before the open on 3 September, the stock opened about $5 below the previous close, and any stop sitting in that gap filled lower than planned. Cut your size, or step aside, before earnings dates and scheduled data releases.
Cap your daily losses
A run of losses on a volatile stock tempts traders to chase their money back. A daily stop loss, a fixed amount after which you stop trading for the day, takes that decision out of your hands.
Final Word
Moderna is now priced on a story that's still being written. The next chapter could be a regulatory filing, a lung cancer readout, or another downgrade, and each will hit the share price in a single session. That's the opportunity and the danger in one. Past performance shows MRNA can triple in a day, but it tells you nothing about future results. Trade it small, trade it with stops, and let the market pay you for discipline rather than bravery.
If you want to see how MRNA behaves before committing capital, open a free demo account and trade it on real prices first.
FAQs
Still weighing whether to trade Moderna? Here are quick answers to the questions traders ask most about MRNA.
Are Moderna stocks too risky to trade after the 2026 spike?
The risk is real. MRNA fell about 24% the session after its 177% jump, and it still trades well above analyst targets. Small position sizes, hard stops, and reduced exposure before known events make it manageable, but not safe.
Can I short-sell Moderna shares to profit from falling prices?
Yes. With CFDs, you can open a sell position that gains if the Moderna share price drops. Losses on a short position grow if the price rises, so a stop loss is just as important as on a long trade.
How much money do I need to trade MRNA CFDs?
A Switch Markets live account opens from $50, but that's too little for a stock that moves $10 or more a day. To risk 1% to 2% per trade with stops wide enough for MRNA's normal range, most traders need at least $1,000 to $2,000.
Can I trade Moderna on MetaTrader 5 with Switch Markets?
Switch Markets offers thousands of share CFDs on MT4 and MT5, including major US listings. Search for MRNA in the Symbols window and add it to Market Watch.
Risk Disclosure: The information provided in this article is not intended to give financial advice, recommend investments, guarantee profits, or shield you from losses. Our content is only for informational purposes and to help you understand the risks and complexity of these markets by providing objective analysis. Before trading, carefully consider your experience, financial goals, and risk tolerance. Trading involves significant potential for financial loss and isn't suitable for everyone.
